ILMN · XBRL financial data
Illumina financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (ILMN's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 29, 2024 | Dec 29, 2024 | Mar 30, 2025 | Jun 29, 2025 | Sep 28, 2025 | Dec 28, 2025 | Mar 29, 2026 | Jun 28, 2026 | Sep 27, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 1,122* | 1,076 | 1,112 | 1,080 | 1,104* | 1,041 | 1,059 | 1,084 | 1,159* | 1,091 | 1,159 | 1,129 |
| Cost of revenue | 448* | 409 | 391 | 335 | 376* | 358 | 364 | 351 | 400* | 370 | 389 | 299 |
| Gross profit | 674* | 667 | 721 | 745 | 728* | 683 | 695 | 733 | 759* | 721 | 770 | 830 |
| Research and development | 341* | 339 | 325 | 253 | 256* | 252 | 247 | 229 | 239* | 240 | 252 | 244 |
| Selling, general and administrative | 485* | 439 | 147 | 239 | 279* | 267 | 234 | 277 | 309* | 272 | 273 | 281 |
| Total operating expenses | 838* | 778 | 2,358 | 4 | 553* | 519 | 481 | 506 | 558* | 512 | 525 | 525 |
| Operating income (loss) | (164)* | (111) | (1,637) | 741 | 175* | 164 | 214 | 227 | 201* | 209 | 245 | 305 |
| Interest income | 11* | 12 | 13 | 11 | 10* | 11 | 10 | 9 | 10* | 11 | 8 | 12 |
| Interest expense | 18* | 18 | 20 | 36 | 25* | 25 | 25 | 25 | 26* | 24 | 24 | 24 |
| Other income (expense) | 4* | 8 | (332) | 4 | 27* | 32 | 107 | 9 | 192* | (39) | 31 | (29) |
| Income tax expense (benefit) | 8* | 17 | 12 | 15 | 0* | 51 | 71 | 70 | 43* | 23 | 53 | 44 |
| Net income (loss) | (176) | (126) | (1,988) | 705 | 186 | 131 | 235 | 150 | 334 | 134 | 207 | 220 |
| Earnings per share, basic USD per share | — | (0.79) | (12.48) | 4.43 | — | 0.83 | 1.49 | 0.98 | — | 0.88 | 1.37 | 1.46 |
| Earnings per share, diluted USD per share | — | (0.79) | (12.48) | 4.42 | — | 0.82 | 1.49 | 0.98 | — | 0.87 | 1.35 | 1.43 |
| Weighted average shares, basic millions of shares | 158* | 159 | 159 | 159 | 159* | 159 | 157 | 153 | 151* | 153 | 151 | 151 |
| Weighted average shares, diluted millions of shares | 158* | 159 | 159 | 160 | 158* | 159 | 157 | 154 | 154* | 154 | 153 | 154 |
Balance sheet
CSVFiscal quarters (ILMN's year ends in late December)
Cash flows
CSVFiscal quarters (ILMN's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 29, 2024 | Dec 29, 2024 | Mar 30, 2025 | Jun 29, 2025 | Sep 28, 2025 | Dec 28, 2025 | Mar 29, 2026 | Jun 28, 2026 | Sep 27, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (176) | (126) | (1,988) | 705 | 186 | 131 | 235 | 150 | 334 | 134 | 207 | 220 |
| Stock-based compensation | 94* | 96 | 112* | 83* | 79* | 73 | 69* | 70* | 63* | 60 | 73* | 74* |
| Depreciation and amortization | year only | 108 | 105 | 70 | 71* | 69 | 68 | 67 | 66* | — | — | — |
| Net cash from operating activities | 224* | 77 | 80* | 316* | 364* | 240 | 234* | 284* | 321* | 289 | 201* | 419* |
| Purchases of property and equipment | 51* | 36 | 31* | 32* | 29* | 32 | 30* | 31* | 55* | 38 | 40* | 40* |
| Net cash from investing activities | (85)* | (48) | (41)* | (41)* | (48)* | (63) | (49)* | (51)* | 108* | (366) | (122)* | 50* |
| Proceeds from issuing common stock | 0* | 36 | 0* | 20* | 0* | 27 | 1* | 16* | 0* | 24 | 0* | 22* |
| Share repurchases | 0* | 0 | 0* | 99* | 17* | 200 | 370* | 130* | 42* | 242 | 128* | 9* |
| Proceeds from long-term debt | year only | — | — | — | 0* | — | — | — | 495* | — | — | — |
| Net cash from financing activities | (27)* | 35 | (226)* | (332)* | (47)* | (195) | (371)* | (115)* | (63)* | (251) | (129)* | (222)* |
| Net change in cash | 121* | 60 | (188)* | (51)* | 258* | (14) | (179)* | 116* | 368* | (329) | (49)* | 249* |
Compare with peers
SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Quarter |
|---|---|---|---|---|---|
| Illumina | 1,289 | 1,129 | 419* | 151.2M | 10-QSep 27, 2026 |
| Avantor | 464 | 1,698 | 195* | 677.6M | 10-QSep 30, 2026 |
| Revvity | 1,023 | 730 | 192* | 111.6M | 10-QJul 5, 2026 |
| Badger Meter | 68 | 236 | 43* | 28.6M | 10-QSep 30, 2026 |
| MKS | 454 | 1,248 | 243* | 67.6M | 10-QJun 30, 2026 |
| Teradyne | 461 | 1,306 | 314* | 156.1M | 10-QSep 27, 2026 |
| Itron | 840 | 599 | 102* | 43.9M | 10-QSep 30, 2026 |
| Vontier | 266 | 757 | 116* | 135.2M | 10-QJul 3, 2026 |
| Bio-Rad Laboratories | 517 | 651 | 99* | not reported | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.